Expanded patent protection for Cereno Scientific’s novel IP Receptor Agonist CS585 through issued patent in China
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a new patent has been granted in China for the second patent family of the preclinical IP Receptor Agonist Program, which includes drug candidate CS585.“We are delighted to obtain further patent protection covering our novel IP receptor agonist CS585. With the addition of China, one of the largest pharmaceutical markets, globally, we have now secured immaterial rights for CS585 on three continents. This expanded IP protection